Scholarlink

<p>Elderly colorectal cancer (CRC) patients face high risks of postoperative depression state, inadequately addressed by opioid-based analgesia. Esketamine, an NMDA receptor antagonist with rapid antidepressant effects, offers potential benefits but lacks evidence in this population. This double-blind RCT enrolled 99 elderly (≥ 65 years) CRC resection patients, randomized to three postoperative PCA groups: C: Sufentanil (2&#xa0;µg/kg) + saline placebo, ES1: Sufentanil + esketamine 1&#xa0;mg/kg, ES2: Sufentanil + esketamine 2&#xa0;mg/kg. Primary outcomes were anxiety/depression (HAMA/HAMD scores) at 24&#xa0;h postoperatively. Secondary outcomes included VAS pain scores, patient satisfaction, and adverse events. Depression/Anxiety: Both esketamine groups showed significantly lower HAMD/HAMA scores vs. control at 24&#xa0;h and 72&#xa0;h (e.g., 24&#xa0;h HAMD: ES1 6.16 ± 2.16, ES2 7.10 ± 2.55 vs. C 9.87 ± 3.67; <i>p</i> &lt; 0.001), with no dose-dependent difference (<i>p</i> &gt; 0.05 ES1 vs. ES2). Pain Control: No intergroup differences in resting/activity VAS scores or rescue analgesia demands (<i>p</i> &gt; 0.05). Satisfaction: Higher satisfaction rates in ES1 (77.4%) and ES2 (90.0%) vs. C (50.0%) (<i>p</i> = 0.002). Safety: Comparable adverse events across groups (<i>p</i> &gt; 0.05). Low-dose esketamine (1&#xa0;mg/kg) adjunct to sufentanil PCA significantly reduces postoperative depression and anxiety state in elderly CRC patients without enhancing analgesia or increasing adverse events. Its profound psychological benefits and high patient satisfaction support its integration into enhanced recovery protocols for this vulnerable cohort. Registry: Chinese Clinical Trial Registry(chictr.org.cn), TRN: ChiCTR2300070763, Registration date: 23 April 2023.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Rong Ding,
  • Daojie Wang,
  • Guoxin Wang,
  • Yamei Lin,
  • Dongchen Wu,
  • Min Zhang,
  • Yufei Ren,
  • Wenyue Kang,
  • Guanwen Lin

摘要

Elderly colorectal cancer (CRC) patients face high risks of postoperative depression state, inadequately addressed by opioid-based analgesia. Esketamine, an NMDA receptor antagonist with rapid antidepressant effects, offers potential benefits but lacks evidence in this population. This double-blind RCT enrolled 99 elderly (≥ 65 years) CRC resection patients, randomized to three postoperative PCA groups: C: Sufentanil (2 µg/kg) + saline placebo, ES1: Sufentanil + esketamine 1 mg/kg, ES2: Sufentanil + esketamine 2 mg/kg. Primary outcomes were anxiety/depression (HAMA/HAMD scores) at 24 h postoperatively. Secondary outcomes included VAS pain scores, patient satisfaction, and adverse events. Depression/Anxiety: Both esketamine groups showed significantly lower HAMD/HAMA scores vs. control at 24 h and 72 h (e.g., 24 h HAMD: ES1 6.16 ± 2.16, ES2 7.10 ± 2.55 vs. C 9.87 ± 3.67; p < 0.001), with no dose-dependent difference (p > 0.05 ES1 vs. ES2). Pain Control: No intergroup differences in resting/activity VAS scores or rescue analgesia demands (p > 0.05). Satisfaction: Higher satisfaction rates in ES1 (77.4%) and ES2 (90.0%) vs. C (50.0%) (p = 0.002). Safety: Comparable adverse events across groups (p > 0.05). Low-dose esketamine (1 mg/kg) adjunct to sufentanil PCA significantly reduces postoperative depression and anxiety state in elderly CRC patients without enhancing analgesia or increasing adverse events. Its profound psychological benefits and high patient satisfaction support its integration into enhanced recovery protocols for this vulnerable cohort. Registry: Chinese Clinical Trial Registry(chictr.org.cn), TRN: ChiCTR2300070763, Registration date: 23 April 2023.